MedPath

Tagged News

Intermountain Health Pioneers First Remote CAR-T Cell Collection Site in Southern Utah

CAR-TOncology
  • Intermountain Health has established the nation's first remote CAR-T cell collection site at St. George Regional Hospital, bringing advanced cancer treatment closer to patients in Southern Utah and Nevada.
  • The innovative satellite clinic eliminates the need for patients to travel hundreds of miles to Salt Lake City for initial collection procedures, significantly improving accessibility to this cutting-edge immunotherapy.
  • CAR-T cell therapy, which reprograms patients' immune cells to target and destroy cancer cells, has shown remarkable success in treating various hematologic cancers including leukemia, lymphoma, and multiple myeloma.

HCW Biologics Secures $5 Million in Follow-On Financing to Advance Immunotherapy Pipeline

CAR-T
  • HCW Biologics has successfully raised $5 million in a follow-on offering to fund clinical development of its novel immunotherapies targeting inflammation-related diseases, particularly its Phase 1 trial of HCW9302 for autoimmune disorders.
  • The company is advancing over 50 proprietary compounds developed through its TOBI and TRBC platforms, with plans to commercialize HCW9206, a promising reagent that could revolutionize CAR-T manufacturing by improving cell persistence and reducing costs.
  • Despite financial challenges, HCW Biologics is implementing a multi-step financing strategy while pursuing business development opportunities, including a potential $7 million licensing deal with WY Biotech for its HCW11-006 compound.

CAR-T Cell Therapy Funding Surges to $141.2 Billion as Industry Expands Globally

Drug ApprovalCAR-TOncology
  • The CAR-T cell therapy industry has raised over $141.2 billion through various financing mechanisms, with estimates suggesting total industry funding could reach $281.7 billion when including undisclosed deals.
  • More than 170 companies worldwide are developing CAR-T products with 1,944 therapies in development, while 13 CAR-T cell therapies have received regulatory approval globally since 2017.
  • Despite a slowdown in IPOs and M&A activity in 2024, venture capital funding remains strong with 89 CAR-T companies securing $7.7 billion since 2014, supporting advancement in both blood cancer and solid tumor applications.

AstraZeneca Acquires EsoBiotec for $1 Billion: Revolutionary In Vivo CAR-T Technology to Transform Cancer Treatment

CAR-TOncology
• Belgian biotech EsoBiotec, founded by Congolese-born scientist Jean-Pierre Latere, has been acquired by AstraZeneca for $1 billion, including $425 million upfront and $575 million in milestone payments.
• EsoBiotec's groundbreaking Engineered NanoBody Lentiviral (ENaBL) platform enables in vivo CAR-T cell therapy, turning patients into their own cell therapy factories and potentially eliminating complex ex vivo manufacturing processes.
• The acquisition represents a remarkable success story for a capital-constrained startup that operated on just €22 million, compared to competitors who raised hundreds of millions for similar technology development.

Cellectis Advances Gene Editing with Non-Viral TALEN Technology and TALE Base Editors at ASGCT 2025

Gene EditingCAR-TOncology
  • Cellectis presents breakthrough research on TALEN-mediated non-viral transgene insertion technology that addresses manufacturing constraints and genomic toxicity risks associated with traditional viral methods.
  • The company's TALE base editors (TALEB) demonstrate high-fidelity C-to-T editing with no detectable off-target effects in primary cells, enhancing specificity for therapeutic applications.
  • Research shows circular single-stranded DNA templates maintain better hematopoietic stem cell fitness and provide more stable gene editing compared to viral donor templates.
  • These innovations expand Cellectis' gene editing toolbox for developing next-generation therapies targeting cancer, autoimmune diseases, and monogenic disorders.

Cell Therapy Advances Show Promise for Hepatocellular Carcinoma Treatment

CAR-T
  • Cellular therapies including CAR-T cells, NK cells, and tumor-infiltrating lymphocytes demonstrate significant potential for treating hepatocellular carcinoma, with encouraging results in preclinical and clinical trials.
  • Multiple cell therapy approaches target specific antigens like GPC3 and AFP, showing enhanced anti-tumor responses when combined with immune checkpoint inhibitors or other immunotherapeutic strategies.
  • Despite promising outcomes, challenges remain including tumor microenvironment immunosuppression, manufacturing complexities, and the need for improved patient selection criteria and long-term safety assessment.
  • Combination strategies integrating cellular therapies with established treatments like surgery, chemotherapy, and immunotherapy could create synergistic effects to enhance overall treatment effectiveness for HCC patients.

Anti-GPC3 CAR T for Treating Patients With Advanced HCC

NCT02395250CompletedPhase 1
RenJi Hospital
Posted 3/1/2015

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

NCT03175679Unknown StatusPhase 1
Beijing YouAn Hospital
Posted 5/1/2017

Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

NCT05213637Unknown StatusPhase 2
Chinese PLA General Hospital
Posted 4/25/2018

CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma

NCT03146234CompletedNot Applicable
RenJi Hospital
Posted 3/17/2017

A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation

NCT02719782Unknown StatusPhase 1
Lion TCR Pte. Ltd.
Posted 7/2/2015

Single Arm Clinical Trial (Gut Microbiota and HCC)

NCT06563947Not Yet RecruitingPhase 2
Xu Yong, MD
Posted 8/24/2024

Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation

NCT01147380CompletedPhase 1
Seigo Nishida
Posted 6/1/2010

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

NCT01239134CompletedPhase 1
Leap Therapeutics, Inc.
Posted 10/1/2010

Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer

NCT03008343CompletedPhase 1
Fuda Cancer Hospital, Guangzhou
Posted 12/1/2016

Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

NCT05339321Unknown StatusPhase 1
Peking Union Medical College Hospital
Posted 4/14/2021

Hydrogel-Coated Membranes Reduce T-Cell Exhaustion in CAR-T Manufacturing

CAR-T
  • Researchers developed bio-functional hydrogel-coated membranes (HCMs) that significantly reduce T-cell exhaustion during CAR-T manufacturing compared to industry standard TransAct activation methods.
  • The HCM platform using combinations of anti-CD3, anti-CD28, anti-4-1BB, and anti-OX40 co-stimulatory molecules promotes central memory T-cell phenotypes while maintaining robust activation and proliferation.
  • CAR-T cells produced using the optimized HCM combination demonstrated superior killing efficacy against target cancer cells, achieving 28% cytolysis compared to 19% with conventional methods.

Long-Term Follow-Up of TRANSFORM Trial Shows Sustained Benefits of Liso-Cel CAR T-Cell Therapy in Relapsed LBCL

CAR-TOncologyReal World Evidence
  • Three-year follow-up data from the phase 3 TRANSFORM trial demonstrates lisocabtagene maraleucel (liso-cel) significantly improved event-free survival with a median of 29.5 months versus 2.4 months with standard of care in relapsed large B-cell lymphoma.
  • Liso-cel showed impressive efficacy with an 87% overall response rate and 74% complete response rate, while maintaining a favorable safety profile with lower rates of cytokine release syndrome and neurotoxicity compared to axicabtagene ciloleucel.
  • The study revealed that patients who received liso-cel as second-line therapy had substantially better outcomes than those who crossed over after standard chemotherapy, emphasizing the importance of early CAR T-cell intervention.

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

NCT04531046Active, Not RecruitingPhase 2
The Lymphoma Academic Research Organisation
Posted 3/10/2021

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

NCT03483103CompletedPhase 2
Juno Therapeutics, a Subsidiary of Celgene
Posted 7/27/2018

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466CompletedPhase 3
Kite, A Gilead Company
Posted 1/25/2018

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

NCT03575351CompletedPhase 3
Celgene
Posted 10/23/2018

Chimeric Therapeutics Raises $6.6 Million to Advance Novel CAR-T and NK Cell Cancer Therapies

CAR-TOncology
  • Chimeric Therapeutics has secured $6.6 million through a two-tranche placement from institutional and professional investors to accelerate its clinical trial pipeline.
  • The funding will primarily support the advancement of CHM CDH17 CAR-T therapy, the first anti-CDH17-directed CAR-T treatment, and CORE-NK cell therapy programs for various cancer types.
  • Patient recruitment and dosing are progressing at major U.S. cancer centers, with the University of Chicago Medicine joining as a new trial site for the pioneering CDH17 CAR-T therapy.

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

NCT06055439RecruitingPhase 1
Chimeric Therapeutics
Posted 5/15/2024

Dasatinib Plus CAR T-Cell Therapy Achieves 85% Complete Molecular Remission in Newly Diagnosed Ph+ ALL

CAR-T
  • A phase 2 trial of 28 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia demonstrated an 85% complete molecular remission rate following CD19 CAR T-cell therapy combined with dasatinib.
  • The treatment protocol achieved 100% complete hematological remission after induction therapy and showed excellent safety with only grade 1 cytokine release syndrome reported.
  • Two-year overall survival and leukemia-free survival rates reached 92%, with patients having IKZF1 alterations showing inferior outcomes compared to those without these genetic changes.

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

NCT04788472CompletedPhase 2
Zhejiang University
Posted 3/5/2021

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.